GlassScriptPhysician profile
Mohammed Shreiba
NPI 1982866067
$1,350.63
in general payments reported to CMS, 2019-2025
17 companies · $22.90 in 2025
The $22.90 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $554 · 2022: $44.62 · 2023: $299 · 2024: $431 · 2025: $22.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $752.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $529.80 | 2021-2024 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $175.18 | 2021-2023 | Rexulti, Nuedexta |
| Janssen Pharmaceuticals, INC | $127.19 | 2023-2024 | Spravato, Invega Sustenna, Invega |
| Teva Pharmaceuticals USA, INC. | $96.44 | 2021-2024 | Austedo Xr |
| Neurocrine Biosciences, INC. | $91.59 | 2021-2023 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $51.10 | 2021 | |
| Acadia Pharmaceuticals INC | $48.99 | 2022-2023 | Nuplazid |
| Eisai INC. | $43.39 | 2021 | |
| Vanda Pharmaceuticals INC. | $32.18 | 2021 | |
| Supernus Pharmaceuticals, INC. | $22.90 | 2025 | |
| Owp Pharmaceuticals, INC. | $21.92 | 2023 | Lamotrigine, Subvenite |
| Alfasigma USA, INC. | $21.58 | 2021 | |
| Avanir Pharmaceuticals, INC. | $20.72 | 2022 | |
| Jazz Pharmaceuticals INC. | $18.71 | 2021 | |
| Adlon Therapeutics L.P. | $17.48 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $16.32 | 2021 | |
| Uswm, LLC | $15.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Shreiba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.